-
公开(公告)号：US08563592B2
公开(公告)日：2013-10-22
申请号：US13083424
申请日：2011-04-08
申请人： Bastiaan Nuijen , Ernie Pfadenhauer , Jos H. Beijnen , Dorla Mirejovsky , Guru Reddy , Luigi Lenaz
发明人： Bastiaan Nuijen , Ernie Pfadenhauer , Jos H. Beijnen , Dorla Mirejovsky , Guru Reddy , Luigi Lenaz
IPC分类号： A61K31/404 , A61K31/405
CPC分类号： A61K31/404 , A61K9/0019 , A61K9/0034 , A61K9/08 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/26
摘要： Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
摘要翻译： 公开了包含吲哚醌化合物和各种膀胱癌治疗和方法的治疗组合物。 更具体地，组合物包含吲哚醌化合物和制剂载体。 制剂载体改善了吲哚醌化合物的溶解度和稳定性。 另外，涂层组合物可以包括涂层剂，其在涂层组合物的膀胱内递送期间提供涂层组合物对膀胱壁的更好的粘附。
-
公开(公告)号：US20110288143A1
公开(公告)日：2011-11-24
申请号：US13083424
申请日：2011-04-08
申请人： Bastiaan Nuijen , Ernie Pfadenhauer , Jos H. Beijnen , Dorla Mirejovsky , Guru Reddy , Luigi Lenaz
发明人： Bastiaan Nuijen , Ernie Pfadenhauer , Jos H. Beijnen , Dorla Mirejovsky , Guru Reddy , Luigi Lenaz
IPC分类号： A61K31/404 , A61P35/00
CPC分类号： A61K31/404 , A61K9/0019 , A61K9/0034 , A61K9/08 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/26
摘要： Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
摘要翻译： 公开了包含吲哚醌化合物和各种膀胱癌治疗和方法的治疗组合物。 更具体地，组合物包含吲哚醌化合物和制剂载体。 制剂载体改善了吲哚醌化合物的溶解度和稳定性。 另外，涂层组合物可以包括涂层剂，其在涂层组合物的膀胱内递送期间提供涂层组合物对膀胱壁的更好的粘附。
-
公开(公告)号：US20090163570A1
公开(公告)日：2009-06-25
申请号：US12396158
申请日：2009-03-02
申请人： Dorla Mirejovsky , Guru Reddy , Luigi Lenaz
发明人： Dorla Mirejovsky , Guru Reddy , Luigi Lenaz
IPC分类号： A61K31/404
CPC分类号： A61K31/404 , A61K9/0034 , A61K31/12 , A61K31/396 , A61K31/405 , A61K31/407 , A61K45/06 , C12Q1/66 , G01N33/533 , G01N33/542 , G01N33/58 , A61K2300/00
摘要： Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments.
摘要翻译： 本文公开了各种膀胱癌治疗和方法。 本公开可以利用人类移行细胞癌中的丙二醇浓度和/或NAD（P）H：醌氧化还原酶-1（NQO1），细胞色素P450氧化还原酶（P450R）和葡萄糖转运蛋白1（Glut-1）蛋白表达 膀胱提供单独针对性的膀胱癌治疗。
-
公开(公告)号：US20070185188A1
公开(公告)日：2007-08-09
申请号：US11673537
申请日：2007-02-09
申请人： Dorla Mirejovsky , Guru Reddy , Luigi Lenaz
发明人： Dorla Mirejovsky , Guru Reddy , Luigi Lenaz
IPC分类号： A61K31/405
CPC分类号： A61K31/404 , A61K9/0034 , A61K31/12 , A61K31/396 , A61K31/405 , A61K31/407 , A61K45/06 , C12Q1/66 , G01N33/533 , G01N33/542 , G01N33/58 , A61K2300/00
摘要： Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments.
摘要翻译： 本文公开了各种膀胱癌治疗和方法。 本公开可以利用人类移行细胞癌中的丙二醇浓度和/或NAD（P）H：醌氧化还原酶-1（NQO1），细胞色素P450氧化还原酶（P450R）和葡萄糖转运蛋白1（Glut-1）蛋白表达 膀胱提供单独针对性的膀胱癌治疗。
-
公开(公告)号：US06709674B2
公开(公告)日：2004-03-23
申请号：US10137205
申请日：2002-05-01
申请人： Dorla Mirejovsky
发明人： Dorla Mirejovsky
IPC分类号： A61K948
CPC分类号： A61K47/12 , A61K9/0019 , A61K31/66 , A61K47/02 , A61K47/26
摘要： The invention includes a packaged liquid composition of a pamidronate alkaline salt in a sealed storage vessel having an inner surface which is non-reactive with the pamidronate alkaline salt composition.
摘要翻译： 本发明包括在密封储存容器中的帕米膦酸盐碱盐的包装液体组合物，其具有与帕米膦酸盐碱性盐组合物不反应的内表面。
-
公开(公告)号：US06906047B2
公开(公告)日：2005-06-14
申请号：US10319377
申请日：2002-12-13
申请人： Dorla Mirejovsky , Michael Burkhart
发明人： Dorla Mirejovsky , Michael Burkhart
IPC分类号： A61K31/675 , A61K47/02 , A61K47/12 , A61K47/18 , A61K31/66
CPC分类号： A61K31/675 , A61K9/0019 , A61K47/02 , A61K47/12 , A61K47/18
摘要： This invention is directed towards a ready-to-use aqueous composition of ifosfamide. In one embodiment, the invention is directed to an aqueous ifosfamide composition which comprises ifosfamide, a pharmaceutically acceptable buffer, and water. The concentration of ifosfamide in the composition may be between about 40 mM and about 400 mM. The concentration of buffer in the composition may be between about 10 mM and about 260 mM. The molar ratio of ifosfamide to buffer may be between about 0.5:1 to about 20:1. The pH of the composition may be between about 4 and about 8.
摘要翻译： 本发明涉及即用型异环磷酰胺的水性组合物。 在一个实施方案中，本发明涉及含有异环磷酰胺，药学上可接受的缓冲液和水的异环磷酰胺组合物。 组合物中异环磷酰胺的浓度可以在约40mM至约400mM之间。 组合物中缓冲液的浓度可以在约10mM至约260mM之间。 异环磷酰胺与缓冲液的摩尔比可以在约0.5:1至约20:1之间。 组合物的pH可以在约4至约8之间。
-
公开(公告)号：US07153840B2
公开(公告)日：2006-12-26
申请号：US10445306
申请日：2003-05-23
IPC分类号： A61K31/7076
CPC分类号： A61K9/0095 , A61K9/0019 , A61K9/0048 , A61K31/70 , A61K31/7076 , A61K47/02 , A61K47/26
摘要： This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration of fludarabine phosphate in the composition may be between about 0.5 mg/mL and about 50 mg/mL. The pH of the composition may be between about 5.5 and about 7.1.
摘要翻译： 本发明涉及磷酸氟达拉滨的即用型水性组合物。 在一个实施方案中，本发明涉及磷酸氟阿拉伯磷酸盐组合物，其包含氟达拉滨磷酸盐，碱和水。 组合物中氟达拉滨磷酸盐的浓度可以在约0.5mg / mL至约50mg / mL之间。 组合物的pH可以在约5.5至约7.1之间。
-
公开(公告)号：US6147122A
公开(公告)日：2000-11-14
申请号：US247449
申请日：1999-02-10
IPC分类号： A61K9/00 , A61K9/107 , A61K31/05 , A61K47/02 , A61K47/10 , A61K47/14 , A61K47/24 , A61K47/44 , A61P23/00 , A61P25/20 , A61K31/10
CPC分类号： A61K9/0019 , A61K31/05 , A61K47/02 , A61K9/1075
摘要： Sterile pharmaceutical compositions for parenteral administration containing 2,6-diisopropylphenol (propofol) are described for use as anesthetics. The compositions comprise an oil-in-water emulsion of propofol additionally comprising an amount of sulfite sufficient to prevent significant growth of microorganisms for at least 24 h after adventitious contamination.
-
9.发明授权
公开(公告)号：US6136850A
公开(公告)日：2000-10-24
申请号：US16931
申请日：1993-02-12
IPC分类号： A61K31/195 , A61K31/198 , A61P27/02 , C09K3/00 , C11D3/00 , C11D3/20 , C11D3/34 , G02C13/00 , A61K31/355 , A61K31/07 , A61K31/34
CPC分类号： C11D3/0078 , C11D3/2096 , C11D3/3427 , Y10S514/912
摘要： Methods and compositions for inhibiting the formation of proteinaceous and/or lipid deposits on a contact lens are disclosed. In one embodiment, the present method comprises contacting a contact lens being worn in a mammalian eye with at least one ophthalmically acceptable antioxidant component in an amount effective to inhibit the formation of at least one of proteinaceous deposits and lipid deposits on the contact lens in the eye.
摘要翻译： 公开了用于抑制隐形眼镜上蛋白质和/或脂质沉积物形成的方法和组合物。 在一个实施方案中，本方法包括将佩戴在哺乳动物眼睛中的隐形眼镜与至少一种眼科可接受的抗氧化剂组分接触，所述组合物有效地抑制在所述隐形眼镜中的至少一种蛋白质沉积物和脂质沉积物的形成 眼。
-
10.发明授权Compositions and methods of enhancing transdermal and transmembrane penetration systemic agents 失效增强透皮和跨膜渗透系统药物的组合物和方法
公开(公告)号：US4743588A
公开(公告)日：1988-05-10
申请号：US620229
申请日：1984-06-13
申请人： Dorla Mirejovsky , Harun Takruri
发明人： Dorla Mirejovsky , Harun Takruri
IPC分类号： C07D295/18 , A61K47/22 , C07D295/185 , A61K31/70 , A61K31/16 , A61K31/56
CPC分类号： C07D295/185 , A61K47/22 , A61K9/0014 , Y10S514/947
摘要： Compositions and methods useful for enhancing the transdermal and transmembrane drug delivery of topical and systemic agents. The compositions and methods comprise the active agent together with an effective amount of certain amides of heterocyclic amines as defined herein as penetration enhancers and topically administering to human or animal skin or other membranes the resulting compositions.
摘要翻译： 用于增强局部和全身药物的透皮和跨膜药物递送的组合物和方法。 组合物和方法包括活性剂以及有效量的本文定义的某些酰胺酰胺作为渗透促进剂，并将所得组合物局部给予人或动物皮肤或其它膜。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.03 秒)
